QuiaPEG

Newsroom

Sept 03, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), which develops improved and patentable versions of clinically validated or approved drugs using the company's unique technology platform, announces that the company's CEO, Marcus Bosson, has on 31/8 and 3/9 in total acquired 100,000 shares at an average price of SEK 2.02 and that on 3 September, Board member Anders Vedin has acquired 99,806 shares at an average price of SEK 2.14.

Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message